Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06189963 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
A Phase 1 study of Moderate Alzheimer Disease, sponsored by NKGen Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT06189963 is a Phase 1 study of Moderate Alzheimer Disease that is actively recruiting participants, run by NKGen Biotech. The registered enrollment target is 36 participants. The trial reports 5 study locations across 3 states.
The verdict
NCT06189963, a Phase 1 study of Moderate Alzheimer Disease, is actively recruiting participants, sponsored by NKGen Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL SNK01
Study Locations (5)
California
- Behavioral Research Specialists, LLC - Glendale
- Syrentis Clinical Research - Santa Ana
- Valiance Clinical Research - Tarzana
Florida
- AdventHealth Research Institute - Orlando
Ontario
- Ottawa Memory Clinic - Ottawa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06189963
The ClinicalTrials.gov registry entry for NCT06189963 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NKGen Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06189963 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Ontario.
Frequently Asked Questions
What is clinical trial NCT06189963 about?
NCT06189963 is a clinical study titled "Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease". The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive asse...
What is the current status of trial NCT06189963?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-11-21. Estimated completion is 2026-06.
What conditions does trial NCT06189963 study?
This clinical trial studies the following conditions: Moderate Alzheimer Disease.
What interventions are being tested in trial NCT06189963?
The interventions under investigation include: Placebo (OTHER), SNK01 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06189963?
This trial is sponsored by NKGen Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06189963 being conducted?
This trial has 5 study locations across California, Florida, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.